RxDoctor Payments Data

Winston Scott, MD

Ophthalmology · East Orange, NJNPI 1780729921

Payments from drug & device makers

$3,464in general payments, 2019–2025

Across 111 payments — averaging $31.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$936
  • Sight Sciences, Inc.$667
  • Bausch & Lomb Americas Inc.$521
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$240
  • Aerie Pharmaceuticals, Inc.$236
  • Tarsus Pharmaceuticals, Inc.$216
  • plus $648 from 12 others

What the payments were for

  • Food & beverage$3,464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,464 in reported general payments places this provider in the 70th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$82,536
Medicare patients
251
Services billed
784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost295$161,153
RestasisCyclosporine42$64,065
VyzultaLatanoprostene Bunod151$62,462
XiidraLifitegrast49$58,089
RocklatanNetarsudil Mesylat/Latanoprost120$53,664
CombiganBrimonidine Tartrate/Timolol104$51,611
SimbrinzaBrinzolamide/Brimonidine Tart96$19,989
Alphagan PBrimonidine Tartrate37$18,938
Brimonidine Tartrate201$17,076
Travoprost89$14,826
Latanoprost1,528$14,242
Cyclosporine28$13,536
TyrvayaVarenicline Tartrate14$11,964
Prednisolone Acetate298$11,284
Ketorolac Tromethamine393$9,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$936$295,767478 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$521$120,551200 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$236$58,406135 claims
AlconSimbrinza$200$19,98996 claims
Oyster Point Pharma, Inc.Tyrvaya$64$11,96414 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$240$5,02314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in East Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →